Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Verastem Inc (VSTM)

Verastem Inc (VSTM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 186,484
  • Shares Outstanding, K 44,507
  • Annual Sales, $ 0 K
  • Annual Income, $ -87,370 K
  • EBIT $ -99 M
  • EBITDA $ -100 M
  • 60-Month Beta 0.22
  • Price/Sales 12.68
  • Price/Cash Flow N/A
  • Price/Book 16.16

Options Overview Details

View History
  • Implied Volatility 211.04% ( +63.37%)
  • Historical Volatility 98.87%
  • IV Percentile 90%
  • IV Rank 47.93%
  • IV High 431.36% on 07/18/24
  • IV Low 8.24% on 07/15/24
  • Put/Call Vol Ratio 0.18
  • Today's Volume 188
  • Volume Avg (30-Day) 328
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 6,860
  • Open Int (30-Day) 5,595

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.79
  • Number of Estimates 3
  • High Estimate -0.76
  • Low Estimate -0.86
  • Prior Year -1.02
  • Growth Rate Est. (year over year) +22.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.72 +12.63%
on 11/21/24
6.05 -30.74%
on 12/06/24
+0.40 (+10.55%)
since 11/20/24
3-Month
2.54 +64.96%
on 10/18/24
6.05 -30.74%
on 12/06/24
+1.31 (+45.49%)
since 09/20/24
52-Week
2.10 +99.52%
on 08/05/24
14.22 -70.53%
on 02/06/24
-3.58 (-46.07%)
since 12/20/23

Most Recent Stories

More News
Verastem: Q3 Earnings Snapshot

Verastem: Q3 Earnings Snapshot

VSTM : 4.19 (-5.63%)
Verastem: Q2 Earnings Snapshot

Verastem: Q2 Earnings Snapshot

VSTM : 4.19 (-5.63%)
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments

/CNW/ -- After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovered that Generation X may...

RHHBY : 34.5000 (+0.76%)
ONCY : 0.8310 (-6.36%)
VSTM : 4.19 (-5.63%)
CADL : 8.75 (-12.15%)
FGEN : 0.4000 (+13.09%)
REGN : 701.85 (-0.90%)
ONC.TO : 1.19 (-9.16%)
The Fight Against Pancreatic Cancer: Biotech Firms Develop New Solutions for Rising Gen X Cases

USA News Group – After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovered that Generation X may be experiencing larger per-capita...

ONCY : 0.8310 (-6.36%)
ONC.TO : 1.19 (-9.16%)
RHHBY : 34.5000 (+0.76%)
VSTM : 4.19 (-5.63%)
CADL : 8.75 (-12.15%)
FGEN : 0.4000 (+13.09%)
REGN : 701.85 (-0.90%)
Biotech Innovations Drive Pancreatic Cancer Treatment: Market Expected to Reach $7.4 Billion by 2032

USA News Group – Recognized as one of the most lethal cancers, researchers are striving to improve survival rates for pancreatic cancer patients by focusing on earlier detection. According to Johns Hopkins...

ONCY : 0.8310 (-6.36%)
ONC.TO : 1.19 (-9.16%)
VSTM : 4.19 (-5.63%)
CTMX : 1.0900 (-0.91%)
BNTX : 113.08 (+1.56%)
FGEN : 0.4000 (+13.09%)
Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates

/CNW/ -- USA News Group – Recognized as one of the most lethal cancers, researchers are striving to improve survival rates for pancreatic cancer patients by...

ONCY : 0.8310 (-6.36%)
VSTM : 4.19 (-5.63%)
CTMX : 1.0900 (-0.91%)
BNTX : 113.08 (+1.56%)
FGEN : 0.4000 (+13.09%)
ONC.TO : 1.19 (-9.16%)
Stock Index Futures Rebound from Thursday’s Sell-Off, U.S. Economic Data on Tap

June S&P 500 E-Mini futures (ESM24) are up +0.28%, and June Nasdaq 100 E-Mini futures (NQM24) are up +0.30% this morning, rebounding from yesterday’s slump prompted by strong U.S. economic data, which...

ESM24 : 5,471.89s (-0.09%)
NQM24 : 19,747.29s (-0.08%)
GFS : 41.72 (+1.02%)
LYV : 133.28 (+0.82%)
BA : 177.35 (+0.18%)
NVDA : 134.70 (+3.08%)
DELL : 115.77 (+3.40%)
RNO.FP : 46.820 (+1.17%)
VSTM : 4.19 (-5.63%)
ROST : 149.15 (+0.92%)
MGNI : 16.34 (+3.94%)
DD : 77.28 (+0.56%)
Verastem: Q1 Earnings Snapshot

Verastem: Q1 Earnings Snapshot

VSTM : 4.19 (-5.63%)
Verastem: Q4 Earnings Snapshot

Verastem: Q4 Earnings Snapshot

VSTM : 4.19 (-5.63%)
Verastem: Q3 Earnings Snapshot

Verastem: Q3 Earnings Snapshot

VSTM : 4.19 (-5.63%)

Business Summary

Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib...

See More

Key Turning Points

3rd Resistance Point 4.79
2nd Resistance Point 4.67
1st Resistance Point 4.43
Last Price 4.19
1st Support Level 4.07
2nd Support Level 3.95
3rd Support Level 3.71

See More

52-Week High 14.22
Fibonacci 61.8% 9.59
Fibonacci 50% 8.16
Fibonacci 38.2% 6.73
Last Price 4.19
52-Week Low 2.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar